“We congratulate the project team at Merck on this important advancement in the treatment of invasive fungal infections,” said John Higgins, president and chief executive officer of Ligand Pharmaceuticals. “Ligand's business is thriving with the continued success of our partners with late-stage clinical and regulatory events. This is the second new product expected to be made available in 2014 following the launch of Duavee last month by Pfizer and three additional Ligand-partnered programs are pending approvals in 2014. Captisol is a proven formulation that is garnering more interest by prospective customers and partners given the technology’s elevated profile.”
NOXAFIL injection for intravenous use is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who severely immunocompromised.